TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11429346

Group type: EXPERIMENTAL
Intervention: CaCl(2) 20 mg/kg and protamine 5 mg/kg mixed and infused over 10 min
Number of subjects: 147

Group type: COMPARATOR
Intervention: CaCl(2) 10 mg/kg as a bolus followed by a 10‐min infusion of protamine 5 mg/kg and CaCl(2) 10 mg/kg
Number of subjects: 147
Study: 9153741

Group type: EXPERIMENTAL
Intervention: Collection of urine specimens for Chlamydia trachomatis testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral surveys combined with STD testing
Number of subjects: 0
Study: 8181345

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 micrograms every 6 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.9 percent saline solution (placebo)
Number of subjects: 42
Study: 3948547

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) albuterol (250 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) or subcutaneous albuterol (500 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined data from all three albuterol routes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (0.3 ml, 1:1,000)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV albuterol (250 micrograms), IM albuterol (500 micrograms), or subcutaneous albuterol (500 micrograms)
Number of subjects: 0
Study: 31037360

Group type: EXPERIMENTAL
Intervention: Serum levels of VCAM‐1 in patients with severe OA of the hips
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control cohort (age and sex-matched)
Number of subjects: 100
Study: 30048234

Group type: EXPERIMENTAL
Intervention: Pilot Intervention (PI)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Comparison of Enhanced Intervention (EI) to Pilot Intervention (PI)
Number of subjects: 307
Study: 27816738

Group type: EXPERIMENTAL
Intervention: Routine labour epidural analgesia (EA)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Analgesia on request
Number of subjects: 488
Study: 24885542

Group type: EXPERIMENTAL
Intervention: Full coverage eligibility for 26 weeks
Number of subjects: 1380

Group type: COMPARATOR
Intervention: No coverage
Number of subjects: 1380
Study: 23763767

Group type: EXPERIMENTAL
Intervention: Vaniprevir/P/R
Number of subjects: 0
Study: 20202719

Group type: EXPERIMENTAL
Intervention: Cell telephone CPR instructions
Number of subjects: 0
Study: 19203904

Group type: EXPERIMENTAL
Intervention: Coformulated zidovudine/lamivudine/abacavir plus tenofovir
Number of subjects: 23

Group type: COMPARATOR
Intervention: Genotype-guided salvage regimen (Control)
Number of subjects: 23
Study: 17011959

Group type: EXPERIMENTAL
Intervention: Biaxial microincision (1.5 mm)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Coaxial small-incision (2.75 mm)
Number of subjects: 70
Study: 14621243

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0/Definit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Scotchbond1/FiltekP60
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1/SureFil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excite/Tetric Condensable
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Kerr Bonding/Prodigy Condensable
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tenure/Virtuoso
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excite/Tetric flow/Tetric Ceram
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gluma/Solitaire
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Syntac/Cavex Packable
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: One‐step/Pyramid
Number of subjects: 100
Study: 10889104

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: RNFL photography
Number of subjects: 58
Study: 8884508

Group type: EXPERIMENTAL
Intervention: Impedance monitoring
Number of subjects: 132

Group type: COMPARATOR
Intervention: Temperature monitoring
Number of subjects: 132
Study: 1410155

Group type: EXPERIMENTAL
Intervention: Smoking a cigarette prior to the continuous performance task (CPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smoking session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking session
Number of subjects: 0

Group type: COMPARATOR
Intervention: No smoking session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light inhalers (pre-smoked to post-task increase in expired air carbon monoxide)
Number of subjects: 0
Study: 7020176

Group type: EXPERIMENTAL
Intervention: Prophylactic antithymocyte globulin (ATG) given in higher doses before signs of engraftment were evident.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned but implied as standard care without ATG).
Number of subjects: 0
Study: 31869853

Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg along with conventional treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 40
Study: 30307614

Group type: EXPERIMENTAL
Intervention: Sunscreen intervention (SPF 15 applied at ≥ 2 mg cm−2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Typical sunscreen use (own sunscreens applied at < 2 mg cm−2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laboratory study (3 SED from three different spectra)
Number of subjects: 62
Study: 29220421

Group type: COMPARATOR
Intervention: D110
Number of subjects: 1834

Group type: COMPARATOR
Intervention: co-D110
Number of subjects: 1834

Group type: COMPARATOR
Intervention: di-D110
Number of subjects: 1834

Group type: COMPARATOR
Intervention: D150
Number of subjects: 1834
Study: 26110694

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 4-6 × 30 s of all-out cycling efforts at approximately 180% of peak workload with 4-min recovery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MIT) - 40- to 60-min continuous cycling at 60% of peak workload
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both HIT and MIT
Number of subjects: 26
Study: 25713888

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 21134477

Group type: EXPERIMENTAL
Intervention: High weight loss (>5%)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low weight loss (<5%)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No weight loss (0% or gain)
Number of subjects: 76
Study: 19826197

Group type: EXPERIMENTAL
Intervention: Computational method for incorporating patient motion into tomotherapy dose calculations
Number of subjects: 0
Study: 17500624

Group type: EXPERIMENTAL
Intervention: BWLP+SC (MI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: BWLP (SC matched)
Number of subjects: 55
Study: 17160199

Group type: EXPERIMENTAL
Intervention: Lutein (L) and zeaxanthin (Z) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12560305

Group type: COMPARATOR
Intervention: Tramadol 75 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tramadol 75 mg plus droperidol 2.5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tramadol 75 mg plus clonidine 150 microg
Number of subjects: 90
Study: 10581660

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms b.i.d. for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study: 8652903

Group type: EXPERIMENTAL
Intervention: CsA in mixture form
Number of subjects: 45

Group type: COMPARATOR
Intervention: CsA in capsule form
Number of subjects: 45
Study: 2011617

Group type: COMPARATOR
Intervention: 0 g L-Tryptophan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1 g L-Tryptophan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3 g L-Tryptophan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 5 g L-Tryptophan
Number of subjects: 14
Study: 6753949

Group type: EXPERIMENTAL
Intervention: Biofeedback-induced relaxation training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 29076125

Group type: EXPERIMENTAL
Intervention: Baseline intracranial vasculopathy defined by magnetic resonance angiography (MRA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal transcranial Doppler (TCD) velocities
Number of subjects: 110
Study: 28502609

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 482

Group type: COMPARATOR
Intervention: infliximab originator
Number of subjects: 482
Study: 25559299

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) with 10 mL of 1% lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 80
Study: 23966238

Group type: EXPERIMENTAL
Intervention: Glucagon administration
Number of subjects: 37
Study: 21426755

Group type: EXPERIMENTAL
Intervention: No-reflow group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Reflow group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 18768009

Group type: EXPERIMENTAL
Intervention: Immediate assistance in accessing housing and assistance in paying first and last month's rent
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study: 16169312

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 100 IU/kg subcutaneously twice daily (n = 220)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Tinzaparin, 175 IU/kg subcutaneously once daily (n = 218)
Number of subjects: 438
Study: 14616170

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d. and Tegaserod 6 mg b.d.
Number of subjects: 19
Study: 10475720

Group type: EXPERIMENTAL
Intervention: Idazoxan (40mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 81
Study: 10829992

Group type: EXPERIMENTAL
Intervention: Bacterial meningitis patients
Number of subjects: 50
Study: 1815963

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6125202

Group type: EXPERIMENTAL
Intervention: RX 781094 at a dose of 0.1 mg/kg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RX 781094 at a dose of 0.05 mg/kg i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clonidine at a dose of 0.1 mg and 0.2 mg i.v.
Number of subjects: 6
Study: 31990414

Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vismodegib
Number of subjects: 0
Study: 31043453

Group type: EXPERIMENTAL
Intervention: Resilience intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 264
Study: 27891657

Group type: EXPERIMENTAL
Intervention: High obesity risk group (based on parental weight)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Low obesity risk group (based on parental weight)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: High obesity risk group
Number of subjects: 167
Study: 25528523

Group type: EXPERIMENTAL
Intervention: Single-dose vaccination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two-dose vaccination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Three doses in lifetime
Number of subjects: 100
Study: 23807273

Group type: EXPERIMENTAL
Intervention: Dolutegravir 10 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Dolutegravir 25 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: Efavirenz (control) 600 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All DTG treatment groups combined
Number of subjects: 208

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 208
Study: 21061408

Group type: EXPERIMENTAL
Intervention: Standardized intervention material
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Physical activity improvements
Number of subjects: 628
Study: 18669546

Group type: EXPERIMENTAL
Intervention: Exercise referral scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice booklet
Number of subjects: 0
Study: 17520463

Group type: EXPERIMENTAL
Intervention: Etanercept (2 x 50 mg/week)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Etanercept (2 x 25 mg/week)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 62
Study: 14966943

Group type: EXPERIMENTAL
Intervention: pioglitazone intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 85
Study: 11409486

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (filgrastim)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9229279

Group type: EXPERIMENTAL
Intervention: 1-hour interactive seminar and received an informational pamphlet and advance directive forms
Number of subjects: 187

Group type: COMPARATOR
Intervention: Pamphlet and forms only (Control)
Number of subjects: 187
Study: 8134674

Group type: EXPERIMENTAL
Intervention: Thiopental (4‐6.5 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propofol (1.5‐2.5 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both induction agents
Number of subjects: 14
Study: 3123756

Group type: EXPERIMENTAL
Intervention: Mitomycin C plus carmofur (HCFU)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Mitomycin C only
Number of subjects: 170
Study: 29355939

Group type: COMPARATOR
Intervention: Energy-adjusted Dietary Inflammatory Index (E-DII) scores, highest quintile (Q5) vs lowest quintile (Q1)
Number of subjects: 101449

Group type: COMPARATOR
Intervention: E-DII scores during follow up <4 years
Number of subjects: 101449

Group type: COMPARATOR
Intervention: E-DII scores during follow up ≥4 years
Number of subjects: 101449

Group type: COMPARATOR
Intervention: E-DII from food only
Number of subjects: 101449
Study: 27473135

Group type: EXPERIMENTAL
Intervention: 0.45 mg/d oral conjugated equine estrogens (CEE)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 50 μg/d transdermal 17β‐estradiol
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 95
Study: 24439440

Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 323

Group type: COMPARATOR
Intervention: Comparison to previous studies
Number of subjects: 323
Study: 23410710

Group type: EXPERIMENTAL
Intervention: Sedentary behavior measured by accelerometry (≤100 counts per minute during wear-time)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary behavior measured by accelerometry
Number of subjects: 0
Study: 20026378

Group type: EXPERIMENTAL
Intervention: Resistance training + creatine supplementation (RT+CR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resistance training + placebo (RT+PL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Resistance training (CON)
Number of subjects: 27
Study: 18082886

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Evening-dosed latanoprost/timolol fixed combination
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Evening-dosed latanoprost
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Evening-dosed travoprost
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 386
Study: 16476431

Group type: EXPERIMENTAL
Intervention: Hansson hook-pins
Number of subjects: 199

Group type: COMPARATOR
Intervention: AO-screws
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Undisplaced fractures
Number of subjects: 199

Group type: COMPARATOR
Intervention: Displaced fractures
Number of subjects: 199
Study: 12933423

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5% (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% (n = 20)
Number of subjects: 60
Study: 11226091

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg IV preoperatively
Number of subjects: 110

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 110
Study: 9166095

Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) in 5-FU-refractory patients
Number of subjects: 0
Study: 7682052

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Palliative surgery
Number of subjects: 472
Study: 2419019

Group type: EXPERIMENTAL
Intervention: inosine pranobex (INPX) 3 g/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study: 30992012

Group type: EXPERIMENTAL
Intervention: Sport for LIFE: All Island (SFL:AI) physical activity programme for 12 weeks
Number of subjects: 740

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 740
Study: 28552331

Group type: EXPERIMENTAL
Intervention: Neurofeedback therapy (NFT) for 20 sessions over four weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group participated in the same NF sessions from the fifth week to eighth week
Number of subjects: 17
Study: 25837528

Group type: EXPERIMENTAL
Intervention: Methadone (0.3 mg/kg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Fentanyl (12 μg/kg)
Number of subjects: 156
Study: 23473438

Group type: EXPERIMENTAL
Intervention: Verbal Counseling (VC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2Tone Trainer (2TT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 56
Study: 21675332

Group type: EXPERIMENTAL
Intervention: Action Over Inertia intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 24
Study: 19887219

Group type: EXPERIMENTAL
Intervention: Very early mobilization (VEM)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 71
Study: 16722152

Group type: EXPERIMENTAL
Intervention: Escherichia coli Nissle (Mutaflor)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 14746588

Group type: EXPERIMENTAL
Intervention: Contact diode TSCPC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-contact diode TSCPC
Number of subjects: 60
Study: 11519238

Group type: EXPERIMENTAL
Intervention: Nurse specialist home care (half of prenatal care at home)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual prenatal care
Number of subjects: 173
Study: 9766410

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) administration at birth (6 mg/kg elemental magnesium)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 49
Study: 7816872

Group type: COMPARATOR
Intervention: Active drug (15 mg males, 10 mg females)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Rectal suppository (2.5 mg b.i.d. for 3 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral capsule (chronic dosing)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Inhalation (acute dosing)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral and sublingual routes (acute dosing)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fasted and fed states (oral dose)
Number of subjects: 57
Study: 3047526

Group type: EXPERIMENTAL
Intervention: 10 mg/day dydrogesterone continuously
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 20 mg/day dydrogesterone for the first 12 days of each month
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.625 mg/day conjugated oestrogen continuously
Number of subjects: 81
Study: 1378707

Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia (EPI-PCA)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 117
Study: 1002084

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 28005194

Group type: EXPERIMENTAL
Intervention: Dapsone 7.5% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 26134916

Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine once daily (QD)
Number of subjects: 0
Study: 23778768

Group type: EXPERIMENTAL
Intervention: Reciprocal (REC; knee flexion immediately followed by a knee extension exercise)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Traditional (TRA; non-preload; a concentric knee extension exercise)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON; no exercise)
Number of subjects: 33
Study: 21649650

Group type: EXPERIMENTAL
Intervention: Classroom-based programme of physical exercise (week 1)
Number of subjects: 552

Group type: COMPARATOR
Intervention: No programme (week 2)
Number of subjects: 552
Study: 19706374

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR, 4x5 g/day creatine monohydrate for 5 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P, same dose of a dextrose‐ascorbic acid placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 17087116

Group type: EXPERIMENTAL
Intervention: Allergen vaccine atomization inhalation (A group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sublingual allergen vaccine (B group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypodermic injection (C group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (32 healthy subjects)
Number of subjects: 90